Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Prospective European Trial Explores Cancer-Nutrition Links Links

October 1, 2000
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 9 No 10
Volume 9
Issue 10

WASHINGTON-Size matters, especially in epidemiologic studies. The European Prospective Investigations into Cancer and Nutrition (EPIC) was founded on that principle in 1992, said Elio Riboli, MD, ScM, MPH.

WASHINGTON—Size matters, especially in epidemiologic studies. The European Prospective Investigations into Cancer and Nutrition (EPIC) was founded on that principle in 1992, said Elio Riboli, MD, ScM, MPH.

Since then, the EPIC researchers have recruited 484,000 subjects from nine European countries for a multicenter, prospective study of the relationship between dietary, genetic, metabolic, and lifestyle characteristics and the risk of cancer and cardiovascular disease.

Dr. Riboli, chief of the Nutrition and Cancer Unit of the International Agency for Research on Cancer, Lyon, France, described the research project at the 10th Annual Research Conference of the American Institute for Cancer Research (AICR).

“We know that a plant-based diet protects against cancers of the colorectum, stomach, upper aerodigestive tract, and possibly others,” Dr. Riboli said. “We also know that salty foods raise the risk of stomach cancer and that there is information suggesting that eating meat increases colorectal cancer risk. But we need to know more: Which foods? Which vegetables? What is their chemical and physical structure?”

In short, while “eat more fruits and vegetables” may be good advice for the public, more detailed information is needed to determine the role of nutrition in initiating or preventing the development of many cancers, he said.

An advantage of studying populations across Europe (in Denmark, France, Germany, Greece, Italy, the Netherlands, Spain, Sweden, and the United Kingdom) is that wide variations in cancer incidence and dietary practices can be explored.

For instance, Dr. Riboli said, the breast cancer rate in Scotland is four times higher than the rate in Sicily or southern Spain, while the stomach cancer rate is highest in central Spain and northern Italy and lowest in England.

The EPIC researchers have collected a detailed questionnaire from each study subject on diet, lifestyle, illness, medication use, physical activity, alcohol and tobacco use, reproductive and contraceptive history, and socioeconomic factors. Anthropometric measurements have also been taken.

The food questionnaire lists 150 to 300 food choices, and a more detailed inquiry into a 1-day “actual” diet taken from 7% of the respondents will cover 3,000 possible food descriptions and 700 recipes tailored for each country. “At worst,” Dr. Riboli quipped, “we can publish books of recipes, if we fail as cancer researchers.”

To date, the EPIC group has taken blood samples from 387,000 subjects. Blood from each subject is parceled out into 28 small (0.5 mL) plastic straws containing plasma, serum, buffy coat or red blood cells, and stored in liquid nitrogen for study over the next 10 to 15 years. The storage system is designed to withstand power outages as long as 4 months without refilling.

EPIC will use these stored biologic samples to measure biomarkers that will then be correlated with the 17,000 cases of cancer expected to occur in this cohort by 2002. Prediagnostic levels of steroid hormones, insulin-like growth factors, and other metabolic factors will be correlated with inherited genetic susceptibilities.

“We are trying to go beyond the black box of epidemiology and identify mechanisms that lead to cancers,” Dr. Riboli said. This may lead to answers to current puzzles such as whether levels of eicosapentaenoic acid (EPA) from fish oil are related to cancer risk. EPA levels have been shown to be higher in Denmark and lower among a group of vegetarians in Oxford, UK.

These biomarker studies may also lead to improved measurements of data collected on dietary questionnaires, whose accuracy has long been debated by nutrition researchers.

Articles in this issue

HER-2/neu Activation May Predict Breast Cancer Prognosis
Company Offers Computer-Aided Detection of Breast Cancer
Adjuvant Tamoxifen Equally Effective in Black and White Breast Cancer Patients
ASBD, an Interdisciplinary Group, Fights Breast Cancer
How Employers Can Help Caregivers in the Workplace
Only Slight Improvement in Hepatocellular Carcinoma Survival
New BRCA1 Mutations Found in Black and Hispanic Women
Study Shows Profile of At-Risk Elderly Lung Cancer Patients
Scientific Studies Support Strategies to Curb Nicotine Addiction
Smoking Declines Among High School Males, But Not Females
Cuts in Medicare Reimbursement for Cancer Drugs on Hold
New Chemoprevention Trials of COX-2 Inhibitors Underway
Panel to Recommend Changes to Cancer Act
NIH Adjuvant Therapy for Breast Cancer Panel to Address 7 Issues
Data Support Chemo for All Young Breast Cancer Patients

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Related Content

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC

Russ Conroy
June 12th 2025
Article

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML

Ariana Pelosci
June 12th 2025
Article

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

Tim Cortese
June 12th 2025
Article

The developer plans to share topline results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.


In patients 39 years and younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Adverse Sexual Health Outcomes Appear More Likely in Women With CRC

Roman Fabbricatore
June 12th 2025
Article

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Related Content

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC

Russ Conroy
June 12th 2025
Article

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML

Ariana Pelosci
June 12th 2025
Article

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

Tim Cortese
June 12th 2025
Article

The developer plans to share topline results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.


In patients 39 years and younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Adverse Sexual Health Outcomes Appear More Likely in Women With CRC

Roman Fabbricatore
June 12th 2025
Article

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.